207 related articles for article (PubMed ID: 34587553)
1. Surgical excision margins for fibrohistiocytic tumors, including atypical fibroxanthoma and undifferentiated pleomorphic sarcoma: A probability model based on a systematic review.
Jibbe A; Worley B; Miller CH; Alam M
J Am Acad Dermatol; 2022 Oct; 87(4):833-840. PubMed ID: 34587553
[TBL] [Abstract][Full Text] [Related]
2. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
3. Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision.
Tolkachjov SN; Kelley BF; Alahdab F; Erwin PJ; Brewer JD
J Am Acad Dermatol; 2018 Nov; 79(5):929-934.e6. PubMed ID: 29981390
[TBL] [Abstract][Full Text] [Related]
4. Soft tissue sarcomas in dermatology.
Fish FS
Dermatol Surg; 1996 Mar; 22(3):268-73. PubMed ID: 8599739
[TBL] [Abstract][Full Text] [Related]
5. Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management.
Soleymani T; Aasi SZ; Novoa R; Hollmig ST
Dermatol Clin; 2019 Jul; 37(3):253-259. PubMed ID: 31084719
[TBL] [Abstract][Full Text] [Related]
6. Time to recurrence after surgical excision of atypical fibroxanthoma-updated systematic review and meta-analysis.
Phan K; Onggo J
Australas J Dermatol; 2019 Aug; 60(3):e220-e222. PubMed ID: 30793288
[TBL] [Abstract][Full Text] [Related]
7. A case of pleomorphic dermal sarcoma with perineural invasion treated with Mohs micrographic surgery and adjuvant radiation therapy.
Kurtti A; Farhadian J; Meehan S; Madu P; Bradu S
Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499417
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta-analysis of individualized participant data.
Ørholt M; Aaberg FL; Abebe K; Walsh S; Roenigk RK; Venzo A; Schmidt G; Klyver H; Jensen DH; Herly M; Vester-Glowinski PV
J Surg Oncol; 2022 Sep; 126(3):555-562. PubMed ID: 35441377
[TBL] [Abstract][Full Text] [Related]
9. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience.
McCoppin HH; Christiansen D; Stasko T; Washington C; Martinez JC; Brown MD; Zwald FO
Dermatol Surg; 2012 Feb; 38(2):230-9. PubMed ID: 22129349
[TBL] [Abstract][Full Text] [Related]
10. Atypical fibroxanthoma management: Recurrence, metastasis and disease-specific death.
Polcz MM; Sebaratnam DF; Fernández-Peñas P
Australas J Dermatol; 2018 Feb; 59(1):10-25. PubMed ID: 28815551
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous mesenchymal tumors treated with Mohs micrographic surgery: a comprehensive review.
Rosenfeld DJ; Cappel MA; Tolkachjov SN
Int J Dermatol; 2021 Nov; 60(11):1334-1342. PubMed ID: 33715156
[TBL] [Abstract][Full Text] [Related]
12. Atypical Fibroxanthoma.
Chapman LW; Yu SS; Arron ST
Semin Cutan Med Surg; 2019 Mar; 38(1):E65-E66. PubMed ID: 31051027
[TBL] [Abstract][Full Text] [Related]
13. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
14. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).
Helbig D; Ziemer M; Dippel E; Erdmann M; Hillen U; Leiter U; Mentzel T; Osterhoff G; Ugurel S; Utikal J; von Bubnoff D; Weishaupt C; Grabbe S
J Dtsch Dermatol Ges; 2022 Feb; 20(2):235-243. PubMed ID: 35099104
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Atypical Fibroxanthoma Versus Malignant Fibrous Histiocytoma.
Branch LG; Albertini JG; Leshin B
J Craniofac Surg; 2015 Jun; 26(4):e322-3. PubMed ID: 26080249
[TBL] [Abstract][Full Text] [Related]
16. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
17. Pleomorphic Dermal Sarcoma.
Saleh JS; Whittington CP; Bresler SC; Patel RM
Surg Pathol Clin; 2024 Mar; 17(1):153-158. PubMed ID: 38278604
[TBL] [Abstract][Full Text] [Related]
18. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans.
Gloster HM; Harris KR; Roenigk RK
J Am Acad Dermatol; 1996 Jul; 35(1):82-7. PubMed ID: 8682970
[TBL] [Abstract][Full Text] [Related]
19. [Atypical fibroxanthoma and pleomorphic dermal sarcoma].
Ziemer M; Jäger IM; Dippel E
Hautarzt; 2019 Sep; 70(9):661-669. PubMed ID: 31468069
[TBL] [Abstract][Full Text] [Related]
20. Atypical fibroxanthoma and pleomorphic dermal sarcoma: Is superficial infiltration in subcutaneous tissue acceptable in AFX?
van Midden D; Flucke UE; Amir AL; Bonenkamp JJ; Lubeek SFK; Blokx WAM
Ann Diagn Pathol; 2022 Jun; 58():151915. PubMed ID: 35276548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
